# Resistant Starch Metabolic Health Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/resistant-starch-metabolic-health-randomized-trial-evidence-review
Category: evidence-review
Summary: Resistant Starch Metabolic Health Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this fir
Last reviewed: 2026-07-27
Reviewed by: Migaku Evidence Review
# Resistant Starch Metabolic Health Randomized Trial: What the Evidence Says

## Quick Answer

Resistant Starch Metabolic Health Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review | preclinical study | 4 | 2026-04-30 | 10.1007/s13668-026-00766-0 |

## What The Sources Report

- Their increasing prevalence has been strongly associated with the presence of multiple cardiometabolic risk factors-including elevated systolic blood pressure, high low-density lipoprotein cholesterol (LDL-c), elevated body mass index (BMI), and elevated fasting glucose-often exacerbated by unhealthy lifestyle behaviors such as physical inactivity and poor dietary habits. [Tavares Isabela Ribeiro Grangeira (2026); evidence level 4]
- According to the World Health Organization (WHO), these risk factors are interrelated and play a key role in the development of non-communicable diseases (NCDs), particularly cardiovascular diseases. [Tavares Isabela Ribeiro Grangeira (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For resistant starch metabolic health randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Tavares Isabela Ribeiro Grangeira (2026). Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. DOI: 10.1007/s13668-026-00766-0. PMCID: PMC13133204. PMID: 42060241. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13133204/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.